Long-term Outcome of Extranodal NK/T Cell Lymphoma Patients Treated With Postremission Therapy Using EBV LMP1 and LMP2a-specific CTLs
Open Access
- 1 August 2015
- journal article
- clinical trial
- Published by Elsevier in Molecular Therapy
- Vol. 23 (8) , 1401-1409
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Induction of antitumor immunity using dendritic cells electroporated with Polo‐like kinase 1 (Plk1) mRNA in murine tumor modelsCancer Science, 2011
- Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related TumorsThe Journal of Immunology, 2010
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsBlood, 2010
- Phase I study of dexamethasone, methotrexate, ifosfamide, l ‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory extranodal natural killer (NK)/T‐cell lymphoma and leukemiaCancer Science, 2008
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesJournal of Clinical Investigation, 2008
- Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferBlood, 2007
- Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T‐cell lymphomaJournal of Medical Virology, 2007
- Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasmsBone Marrow Transplantation, 2006
- Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's DiseaseJournal of Experimental Medicine, 2004
- Quantitative Analysis of Cell-free Epstein-Barr Virus Genome Copy Number in Patients with EBV-associated Hemophagocytic LymphohistiocytosisLeukemia & Lymphoma, 2002